25 May 2013
Keywords: sepracor, files, nda, xopenex, hfa, mdi, says
Article | 24 May 2004
Sepracor says it has submitted a New Drug Application to the US Food and Drug Administration for Xopenex HFA (levalbuterol ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
29 March 2004
26 January 2004
24 May 2013
© 2013 thepharmaletter.com